Stay updated on Pembrolizumab & Cetuximab in HNSCC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page’s displayed site/version label has been updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a minor maintenance or deployment change with no change to the underlying study information.
    Difference
    0.0%
    Check dated 2026-04-24T06:20:54.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Revision tag updated to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:42:51.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The study’s Conditions list now includes squamous cell carcinoma of the head and neck and nasal cavity/paranasal sinus carcinoma.
    Difference
    0.1%
    Check dated 2026-04-02T15:32:23.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T04:56:38.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    - Revision tag updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-12T00:55:25.000Z thumbnail image
  8. Check
    68 days ago
    Change Detected
    Summary
    Hypopharynx cancer and Oropharynx cancer were added to the Conditions list, and a Genetic and Rare Diseases Information Center resource was added under Resources.
    Difference
    0.2%
    Check dated 2026-02-25T18:37:45.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Cetuximab in HNSCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.